echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Head-to-head superiority data unveiled!

    Head-to-head superiority data unveiled!

    • Last Update: 2021-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The 26th European Hematology Association Annual Meeting (EHA 2021) will be held from June 9 to 17, 2021.


    ®

    According to the interim analysis data, when the median follow-up time was 15 months, Zebutinib achieved a higher ORR (78.


    "Head-to-head" research refers to the use of clinically used therapeutic drugs or methods as direct controls, and clinical trials carried out under the same experimental conditions can be regarded as "direct single-handedness" of two drugs.


    The ALPINE study is a randomized phase 3 head-to-head clinical trial conducted in more than 100 clinical trial centers in many countries around the world.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.